The Cooper Companies (COO) stock falls despite strong Q1 results showing 6.2% revenue growth, 20% EPS jump, and raised guidance amid regional headwinds. The postThe Cooper Companies (COO) stock falls despite strong Q1 results showing 6.2% revenue growth, 20% EPS jump, and raised guidance amid regional headwinds. The post

The Cooper Companies (COO) Stock: Shares Decline Despite Impressive Q1 Earnings Beat and Raised Guidance

2026/03/06 22:56
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Key Highlights

  • First-quarter revenue reached $1.024B, up 6.2%, while COO stock dropped 2.17%.
  • Earnings per share (non-GAAP) surged 20% to $1.10; annual outlook improved.
  • CooperVision segment expanded 7.6% on strength in MyDay and MiSight products.
  • Asia-Pacific region saw 4% sales drop due to legacy hydrogel challenges.
  • CooperSurgical posted 3.3% revenue growth; company generated $159M free cash flow.

Shares of The Cooper Companies, Inc. (COO) experienced downward pressure despite delivering robust fiscal first-quarter results and demonstrating significant earnings momentum. The stock finished at $80.20, down 2.17%, before extending losses to $75.23 in pre-market activity. This market reaction came even as the medical device manufacturer reported enhanced revenue, improved profit margins, and upgraded earnings projections.

The Cooper Companies, Inc., COO

Quarterly results demonstrate robust revenue momentum and profitability gains

The company posted consolidated revenue totaling $1.024 billion for the first fiscal quarter. This represents a 6.2% year-over-year increase from the comparable period. On an organic basis, revenue climbed 2.9%, indicating consistent underlying demand across core business lines.

Profitability metrics showed meaningful improvement as operational discipline and restructuring initiatives delivered benefits. The non-GAAP gross margin came in at 68.1%, while the operating margin expanded to 26.9%. Operating expenses as a percentage of total revenue decreased versus the prior-year quarter.

Non-GAAP diluted earnings per share climbed 20% year over year to reach $1.10 for the period. The share count averaged approximately 197 million during the quarter. Management responded by elevating full-year non-GAAP EPS guidance to a range of $4.58 to $4.66.

Vision care segment benefits from innovative contact lens products

CooperVision generated $695 million in revenue during the quarter, representing 7.6% growth compared to the year-ago period. The division’s organic revenue advanced 3.3%, supported by consistent worldwide demand for contact lens solutions. Innovation initiatives and geographic market penetration drove segment results.

The MyDay premium contact lens portfolio gained traction with stronger uptake across multiple international territories. Meanwhile, MiSight lenses extended their presence in the myopia management category. MiSight product revenue climbed 23% versus last year to total $28 million.

The Asia-Pacific territory presented challenges, with revenue declining 4% during the reporting period. Weakness in traditional hydrogel offerings in the Japanese market primarily accounted for the regional shortfall. Company leadership anticipates continued softness in the current quarter before growth resumes in the third fiscal quarter.

Surgical division demonstrates improving trends and robust cash performance

CooperSurgical recorded quarterly revenue of $329 million, achieving 3.3% year-over-year expansion. On an organic basis, the division grew 2.2%, signaling consistent advancement across its medical device offerings. Fertility-related products displayed early indicators of demand recovery.

The fertility business generated $127 million in quarterly revenue, advancing 3% organically. Improved procedure volumes and stable product demand contributed to segment performance. These results reflect gradual healing in the reproductive health marketplace.

The company produced $159 million in free cash flow during the three-month period. Share repurchase activity totaled 1.1 million shares for $92 million, while management refinanced $950 million in term debt, extending maturity to February 2031. Net debt decreased to approximately $2.4 billion as the balance sheet strengthened.

Leadership remains committed to expanding market position, enhancing operational performance, and maintaining disciplined capital deployment strategies. These priorities underpin sustainable growth prospects across both business segments. Nevertheless, investor sentiment turned negative following the earnings announcement, with shares extending declines into the following trading session.

The post The Cooper Companies (COO) Stock: Shares Decline Despite Impressive Q1 Earnings Beat and Raised Guidance appeared first on Blockonomi.

Market Opportunity
Audiera Logo
Audiera Price(BEAT)
$0.36839
$0.36839$0.36839
+11.72%
USD
Audiera (BEAT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.